Advances in anti-BRAF therapies for lung cancer

Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, D’Angelo, Alberto, Sirico, Marianna, Pittacolo, Matteo, Conter, Felipe Umpierre, Sobhani, Navid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068629/
https://www.ncbi.nlm.nih.gov/pubmed/33474634
http://dx.doi.org/10.1007/s10637-021-01068-8
_version_ 1783683058581372928
author Roviello, Giandomenico
D’Angelo, Alberto
Sirico, Marianna
Pittacolo, Matteo
Conter, Felipe Umpierre
Sobhani, Navid
author_facet Roviello, Giandomenico
D’Angelo, Alberto
Sirico, Marianna
Pittacolo, Matteo
Conter, Felipe Umpierre
Sobhani, Navid
author_sort Roviello, Giandomenico
collection PubMed
description Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0–3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.
format Online
Article
Text
id pubmed-8068629
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-80686292021-05-05 Advances in anti-BRAF therapies for lung cancer Roviello, Giandomenico D’Angelo, Alberto Sirico, Marianna Pittacolo, Matteo Conter, Felipe Umpierre Sobhani, Navid Invest New Drugs Review Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0–3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects. Springer US 2021-01-21 2021 /pmc/articles/PMC8068629/ /pubmed/33474634 http://dx.doi.org/10.1007/s10637-021-01068-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Roviello, Giandomenico
D’Angelo, Alberto
Sirico, Marianna
Pittacolo, Matteo
Conter, Felipe Umpierre
Sobhani, Navid
Advances in anti-BRAF therapies for lung cancer
title Advances in anti-BRAF therapies for lung cancer
title_full Advances in anti-BRAF therapies for lung cancer
title_fullStr Advances in anti-BRAF therapies for lung cancer
title_full_unstemmed Advances in anti-BRAF therapies for lung cancer
title_short Advances in anti-BRAF therapies for lung cancer
title_sort advances in anti-braf therapies for lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068629/
https://www.ncbi.nlm.nih.gov/pubmed/33474634
http://dx.doi.org/10.1007/s10637-021-01068-8
work_keys_str_mv AT roviellogiandomenico advancesinantibraftherapiesforlungcancer
AT dangeloalberto advancesinantibraftherapiesforlungcancer
AT siricomarianna advancesinantibraftherapiesforlungcancer
AT pittacolomatteo advancesinantibraftherapiesforlungcancer
AT conterfelipeumpierre advancesinantibraftherapiesforlungcancer
AT sobhaninavid advancesinantibraftherapiesforlungcancer

Ejemplares similares